Cytek Biosciences, Inc.
$4.57
▲
1.12%
2026-04-21 06:16:01
cytekbio.com
NMS: CTKB
Explore Cytek Biosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$592.62 M
Current Price
$4.57
52W High / Low
$6.18 / $2.37
Stock P/E
—
Book Value
$2.66
Dividend Yield
—
ROCE
-10.52%
ROE
-18.05%
Face Value
—
EPS
$-0.52
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
702
Beta
1.28
Debt / Equity
6.95
Current Ratio
5.04
Quick Ratio
4.42
Forward P/E
100.67
Price / Sales
2.89
Enterprise Value
$344.55 M
EV / EBITDA
-10.5
EV / Revenue
1.71
Rating
Buy
Target Price
$6
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Enovis Corporation | $26.27 | — | $1.52 B | — | -0.58% | -58.27% | $37.85 / $21 | $26.05 |
| 2. | SI-BONE, Inc. | $14.32 | — | $632.45 M | — | -10.47% | -10.97% | $21.89 / $12.15 | $4.07 |
| 3. | NovoCure Limited | $12.67 | — | $1.44 B | — | -26.47% | -38.89% | $20.06 / $9.82 | $3.03 |
| 4. | LivaNova PLC | $65.81 | — | $3.6 B | — | 11.09% | -19.24% | $71.92 / $34 | $21.96 |
| 5. | Electromed, Inc. | $25.4 | 23.98 | $215.65 M | — | 22.29% | 20.2% | $30.73 / $17.73 | $5.49 |
| 6. | Orthofix Medical Inc. | $12.65 | — | $507.83 M | — | -12.14% | -19.34% | $16.99 / $10.24 | $11.3 |
| 7. | Nuwellis, Inc. | $1.16 | — | $2.85 M | — | -359.88% | -3.83% | $45.42 / $0.96 | $1.56 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 62.14 M | 52.29 M | 45.6 M | 41.46 M | 57.48 M | — |
| Operating Profit | -5.59 M | -9.19 M | -10.62 M | -14.97 M | 2.99 M | — |
| Net Profit | -44.08 M | -5.48 M | -5.58 M | -11.4 M | 9.64 M | — |
| EPS in Rs | -0.34 | -0.04 | -0.04 | -0.09 | 0.08 | 0.01 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 201.49 M | 200.45 M | 193.01 M | 164.04 M |
| Operating Profit | -40.38 M | -20.52 M | -27.84 M | -1.8 M |
| Net Profit | -66.54 M | -6.02 M | -12.15 M | 2.58 M |
| EPS in Rs | -0.52 | -0.05 | -0.09 | 0.02 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 461.54 M | 499.5 M | 494.46 M | 519.48 M |
| Total Liabilities | 119.8 M | 103.76 M | 101.39 M | 93.93 M |
| Equity | 341.74 M | 395.74 M | 393.06 M | 425.3 M |
| Current Assets | 392 M | 396.45 M | 392.06 M | 454.02 M |
| Current Liabilities | 77.8 M | 67.66 M | 56.23 M | 49.04 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -4.69 M | 25.38 M | 5.28 M | -12.23 M |
| Investing CF | 10.12 M | -82.97 M | -93.89 M | -55.91 M |
| Financing CF | -13.43 M | -15.82 M | -41.81 M | 5.51 M |
| Free CF | -8.88 M | 21.65 M | 0.45 M | -22.1 M |
| Capex | -4.19 M | -3.73 M | -4.83 M | -9.87 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 3.85% | 17.67% | — | — |
| Earnings Growth % | 50.44% | -571.58% | — | — |
| Profit Margin % | -3% | -6.29% | 1.57% | — |
| Operating Margin % | -10.24% | -14.43% | -1.1% | — |
| Gross Margin % | 55.43% | 56.69% | 61.56% | — |
| EBITDA Margin % | -5.01% | -2.28% | 5.79% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.